GMAB241220C35000
- 0.00
- 0.000.00%
Genmab Newsroom
Scancell Signs New Commercial License Deal With Genmab
Scancell Strikes Deal Worth up to $630m With Genmab | AIM:SCLP, OTC:SCNLF
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab Price Target Lowered to DKK 1,700 From DKK 2,050 at JPMorgan
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Genmab Discloses Share Transactions by Executives
Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?
Top Gap Ups and Downs on Friday: MUFG, UBS, SMFG and More
Genmab A/S Plans Strategic Capital Expansion by 2029
6-K: Report of foreign private issuer (related to financial reporting)
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Genmab to Present at Citi's Global Healthcare Conference
Jefferies Sticks to Their Hold Rating for Genmab A/S (0MGB)
Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?
Genmab Aligns Employee Incentives With Stock Units
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Top Gap Ups and Downs on Tuesday: SMCI, WMT, BBY and More
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating